ALNY Q4 2018 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-44.5% YoY

Gross Profit

$19M92.1% margin

Operating Income

-$220M-1047.7% margin

Net Income

-$211M-1005.3% margin

EPS (Diluted)

$-2.09

QoQ Revenue Growth

+916.6%

Cash Flow

Operating Cash Flow

-$150M

Free Cash Flow

-$188M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$273M

Stockholders' Equity

$1.3B

Cash & Equivalents

$420M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$38M	-44.5%
Gross Profit	$19M	$38M	-48.9%
Operating Income	-$220M	-$147M	-49.6%
Net Income	-$211M	-$142M	-48.7%

Revenue Segments

Product

$12M100%